FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma

Yilin Yu¹, Zhiping Wang¹, Qunhao Zheng¹, Jiancheng Li¹

¹Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, Fujian, China

ABSTRACT

FAM72A–D promote the self-renewal of neural progenitor cells. There is accumulating evidence that FAM72 promotes tumorigenicity. However, its effects in lung adenocarcinoma (LUAD) have not been determined. Thus, we evaluated the prognostic value of FAM72A–D in LUAD using bioinformatics approaches. In particular, we evaluated the relationship between FAM72 and LUAD using a wide range of databases and analysis tools, including TCGA, GEO, GEPIA, Metascape, cBioPortal, and MethSurv. Compared with its expression in normal lung tissues, FAM72 expression was significantly increased in LUAD tissues. A univariate Cox analysis showed that high FAM72 expression levels were correlated with a poor OS in LUAD. Additionally, FAM72 expression was independently associated with OS through a multivariate Cox analysis. GO and GSEA revealed enrichment in mitotic nuclear division and cell cycle. Moreover, high FAM72 expression was associated with poor survival. An analysis of immune infiltration showed that FAM72 is correlated with immune cell infiltration. Finally, we found that the methylation level was associated with prognosis in patients with LUAD. In summary, these results indicate that FAM72 is a potential molecular marker for poor prognosis in LUAD and provide additional insight for the development of therapies and prognostic markers.

INTRODUCTION

Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma are the two main types of non-small cell lung cancer (NSCLC) [1]. LUAD is the most common histological type of NSCLC [2]. Lung cancer has become the second most common cancer in both men and women. It accounts for 25% of all cancer-related deaths. During 2007–2013, the 5-year relative survival rate of lung cancer was only 18%. It is usually diagnosed at a relatively advanced stage [3, 4]. Currently, the treatment for LUAD mainly includes surgical resection, chemotherapy, radiotherapy, and molecular targeted therapy. However, compared with the steadily increasing survival rates for many cancers, the overall survival (OS) for lung cancer has not improved substantially, primarily owing to the lack of effective therapeutic targets [5]. The most important and only curable treatment for LUAD is surgical resection. However, once distant metastasis occurs, LUAD cannot be cured through surgery. Therefore, there is an urgent need to identify novel molecular mechanisms and effective therapeutic targets for LUAD.

FAM72A–D (Family with sequence similarity 72 member A–D) is composed of four human-specific paralogs (A–D). FAM72 is a protein-coding neural stem cell-specific gene [6, 7]. However, under certain conditions, FAM72 may lead to post-mitotic neuronal death and may promote the occurrence and development of cancers in tissues other than neuronal tissues [6, 8, 9], including breast cancer, prostate cancer, and glioblastoma [6, 10, 11]. FAM72 is associated with cancer cell division, proliferation, and differentiation. Additionally, high levels of FAM72 are associated with hypomethylation and affect the prognosis in various cancers [11, 12]. These results suggest that FAM72 is a prognostic biomarker in cancer. However, it has not been established...
as a prognostic factor in LUAD, and its relationship with LUAD has not been reported to date.

In this study, we performed the first analysis of the functions of FAM72 in LUAD. In particular, the Cancer Genome Atlas (TCGA) was utilized to analyze the expression of FAM72A–D and its clinical-prognostic value in LUAD. We validated the prognostic value in four independent datasets from the Gene Expression Omnibus (GEO) database. We first analyzed the expression differences of FAM72 in patients with LUAD between tumor tissue and normal tissue and then explored correlations between expression levels and clinicopathological parameters based on univariate and multivariate Cox regression models. We further developed a nomogram to predict prognosis and analyzed its predictive performance. To gain a more in-depth understanding of the biological mechanisms underlying the effects of FAM72, we performed a Gene Ontology (GO) analysis and a gene set enrichment analysis (GSEA). Finally, we examined the correlations between FAM72 and mutations, immune infiltration, and methylation and comprehensively explored the link between FAM72 and tumorigenesis.

RESULTS

Clinical characteristics

Data (shown in Table 1) were collected from TCGA, including gene expression data and clinical data. Patient characteristics, including age, gender, pack-years, race, tumor site, epithelial growth factor receptor (EGFR) status, anaplastic lymphoma kinase (ALK) status, kirsten rat sarcoma viral oncogene (KRAS) status, TNM stage, pathological stage, and gene expression, were collected.

Expression status of FAM72 in LUAD tissues

As evaluated by the Wilcoxon rank-sum test, the expression of FAM72A–D was significantly higher in LUAD tissues than in normal tissues (P < 0.001) (Figure 1A–1D). FAM72A–D was significantly overexpressed in LUAD (P < 0.001), revealing that the expression of FAM72A–D is associated with lung carcinogenesis. As shown in Figure 1E, there were significant correlations between levels of FAM72A–D genes. The AUC values for FAM72A–D were 0.780 (CI: 0.733–0.826), 0.878 (CI: 0.840–0.917), 0.851 (CI: 0.813–0.890), and 0.843 (CI: 0.807–0.880), respectively (Figure 1F).

Association between FAM72 and survival

OS was significantly reduced in patients with high FAM72A–D expression than in patients with low FAM72A–D expression (P ≤ 0.001) (Figure 2A–2D). To verify the association between FAM72A–D expression and OS, we used the GSE13213, GSE30219, GSE41271, and GSE50081 datasets from the GEO database. In these datasets, OS was significantly reduced in patients with high FAM72 expression than in those with low FAM72 expression (P = 0.009, 0.009, 0.038, and 0.005, respectively) (Figure 2E–2H). We next used a univariate Cox regression model to analyze prognostic factors in LUAD (Table 2). In this analysis, high FAM72 expression levels were correlated with a worse OS. We then performed a multivariate analysis with the Cox regression model. Owing to missing data exceeding 20%, the M stage was not included in this analysis. The results indicated that FAM72A–D expression (all P < 0.01), age, and pathological stage are independently associated with OS. These findings demonstrated that increased FAM72 expression is correlated with a poor OS in LUAD.

Development of a prognostic model based on FAM72 and clinicopathological factors

A nomogram integrating FAM72A–D expression and independent clinical risk factors (age and pathological stage) was constructed (Figure 3A–3D). A worse prognosis was represented by a higher total number of points on the nomogram. The C-index values were 0.7, 0.7, 0.69, and 0.68 for FAM72A–D based on 1000 bootstrap replicates. The deviation correction line in the calibration plot was close to the ideal curve (i.e., a 45° line), indicating that the prediction results are in good agreement with the observation results (Figure 4A–4D).

FAM72-related functional enrichment analysis

A GO enrichment analysis of genes with correlated expression revealed various overrepresented terms in the three main functional groups (Figure 5A–5D): cellular component, biological process, and molecular function. In the cellular component category, FAM72 and genes with similar expression patterns were mainly involved in mitotic nuclear division, spindle, cell cycle, and DNA replication. Figure 6A–6D shows an interactive network of the most highly enriched terms (colored by cluster-ID, where distinct colors indicate enriched pathways).

FAM72-related signaling pathways obtained by GSEA

RNA-seq data obtained from TCGA were used to compare groups with high and low FAM72A–D expression. Approximately 20,000 differentially expressed genes were identified between the high and low expression groups. Based on a GSEA of all differentially expressed genes, various significantly enriched signaling pathways were identified, including EGFR signaling, lung cancer poor survival, undifferentiated cancer, proliferation, and cell cycle, as determined by the
| Clinical characteristics     | Total (497) | Percentage (%) |
|------------------------------|-------------|----------------|
| **Gender**                   |             |                |
| male                         | 228         | 45.9           |
| female                       | 269         | 54.1           |
| **Age**                      |             |                |
| <=70 years old               | 327         | 65.8           |
| > 70 years old               | 160         | 32.2           |
| **Number pack years smoked** |             |                |
| <40                          | 167         | 33.6           |
| >=40                         | 174         | 35             |
| **Race**                     |             |                |
| white                        | 384         | 77.3           |
| other                        | 113         | 22.7           |
| **Tumor site**               |             |                |
| upper lobe                   | 291         | 58.6           |
| other                        | 206         | 41.4           |
| **EGFR status**              |             |                |
| mut                          | 79          | 15.9           |
| wt                           | 190         | 38.2           |
| **ALK status**               |             |                |
| mut                          | 33          | 6.6            |
| wt                           | 206         | 41.4           |
| **KRAS status**              |             |                |
| mut                          | 61          | 12.3           |
| wt                           | 244         | 49.1           |
| **T stage**                  |             |                |
| T1                           | 166         | 33.4           |
| T2                           | 267         | 53.7           |
| T3                           | 43          | 8.7            |
| T4                           | 18          | 3.6            |
| **N stage**                  |             |                |
| N0                           | 321         | 64.6           |
| N1                           | 94          | 18.9           |
| N2                           | 69          | 13.9           |
| N3                           | 2           | 0.4            |
| **M stage**                  |             |                |
| M0                           | 331         | 66.6           |
| M1                           | 24          | 4.8            |
| **TNM stage**                |             |                |
| stage I                      | 267         | 53.7           |
| stage II                     | 118         | 23.7           |
| stage III                    | 80          | 16.1           |
| stage IV                     | 25          | 5              |
| **Vital status**             |             |                |
| dead                         | 180         | 36.2           |
| alive                        | 317         | 63.8           |
| **FAM72A expression**        |             |                |
| low                          | 248         | 49.9           |
| high                         | 249         | 50.1           |
| **FAM72B expression**        |             |                |
| low                          | 248         | 49.9           |
| high                         | 249         | 50.1           |
FAM72C expression

|       | low | high |
|-------|-----|------|
|       | 248 | 249  |
|       | 49.9| 50.1 |
FAM72D expression

|       | low | high |
|-------|-----|------|
|       | 248 | 249  |
|       | 49.9| 50.1 |

normalized enrichment score (NES), adjusted P-value, and false discovery rate (FDR) (Figure 7A–7D). Several pathways enriched in FAM72A–D were related to LUAD, including proliferation, EGFR signaling, undifferentiated cancer, lung cancer poor survival, and cell cycle pathways (Figure 8A).

**Genetic mutations in FAM72 and their associations with OS**

We analyzed genetic alterations in FAM72A–D and their associations with OS in LUAD. As shown in Figure 8B, 8C, patients with LUAD showed a high FAM72A–D mutation rate. Among 510 patients with LUAD, genetic alterations were found in 122 patients, with an overall mutation rate of 24% and specific mutation rates of 14%, 17%, 12%, and 18% for the four loci, respectively. Furthermore, genetic alterations in FAM72A–D were associated with a poor OS in patients with LUAD. These results implied that mutations in FAM72A–D could affect prognosis in LUAD.

**Correlations between FAM72 expression and immune infiltration**

As shown in Table 3, activated CD4 T cells were significantly positively correlated with FAM72A–D expression. In other subsets, we found that FAM72 expression was associated with plasmacytoid dendritic cell, natural killer T cell, monocyte, mast cell, macrophage, immature dendritic cell, eosinophil, activated dendritic cell, type 2 T helper cell, type 17 T helper cell, T follicular helper cell, memory B cell, immature B cell, gamma delta T cell, effector memory CD4 T cell, central memory CD4 T cell, activated CD4 T cell, and activated B cell counts. PDCD1 (PD1) and CD274 (PD-L1) levels were positively correlated with FAM72A–D expression (Table 4).

**Correlation between FAM72 expression and methylation**

As shown in Figure 8A, the methylation level of FAM72 is low. Its expression may be related to the hypomethylation level (Figure 9A–9C). MethSurv was used to evaluate the effect of hypomethylation levels and FAM72 expression on prognosis in LUAD. We discovered that cg09169215, located in a CpG island, was associated with a poor prognosis (Figure 9D).

**DISCUSSION**

Owing to the lack of early clinical features of LUAD, a large number of patients develop metastases [3, 4]. Currently, the primary clinical treatments for advanced LUAD are chemotherapy, radiotherapy, and targeted therapy; however, these approaches are limited with respect to improving survival. Moreover, the prognosis is poor for stage III or higher in NSCLC, with fewer than 15% of patients surviving 5 years [13]. Most patients eventually die from chemotherapy resistance and cancer progression. Therefore, the identification of new molecular mechanisms is necessary to develop therapeutic targets in LUAD.

Our results indicated that FAM72 may be a prognostic biomarker in LUAD. High FAM72 expression was associated with a poor survival rate. FAM72 mutations were also associated with poor survival. FAM72 has been reported to promote cancer cell proliferation in glioblastoma and multiple myeloma [11, 12]. Rahane et al. indicated that the increased expression of mitotic FAM72 in tumor cells is caused by upstream mutations in primitive oncogenes or in tumor suppressor genes, such as EGFR, RAS, BRAF, and TP53, resulting in increased cell proliferation. Silencing neural stem cell-specific FAM72 may prevent cancer cell proliferation [11]. These previous findings suggest that FAM72 is an oncogene.

Similarly, our results demonstrated FAM72 was up-regulated in LUAD tissues, supporting its potential role in the development of LUAD. FAM72 paralogs might contribute to tumorigenesis by the activation of centrosome and mitotic spindle formation via mitotic cell cycle genes KIF23, ASPM, CEP55, KIF14, SGO1, CENPE, and BUB1 [11]. In addition, several studies have shown that FAM72 may be a target for tumor therapy [6, 10–12, 14]. However, the association between FAM72 and LUAD has not been explored to date. Therefore, our results provide the first evidence for its therapeutic and prognostic value in LUAD.

Key terms identified in a GO enrichment analysis, such as mitotic nuclear division, spindle, cell cycle and DNA
Figure 1. FAM72A-D expression levels in LUAD from TCGA data. (A-D) The expression levels of FAM72A-D in LUAD and normal tissue; (E) The correlation between FAM72A-D members; (F) Receiver operating characteristic analysis (ROC) of FAM72A-D in LUAD. (*P < 0.05, **P < 0.01, ***P < 0.001).
Figure 2. The prognostic value of FAM72A-D expression in LUAD. (A–D) Survival curves of OS from TCGA data (n = 497); (E–H) Survival curves of OS from GSE 13213, GSE30219, GSE41271 and GSE50081 data (n = 117, 85, 181, and 127, respectively).
Table 2. Univariate(a) and multivariate(b) Cox regression model of prognosis for FAM72A-D in patients with lung adenocarcinoma.

| Clinicopathologic variable                                      | Total(N) | HR(95% CI)         | p-value |
|---------------------------------------------------------------|----------|--------------------|---------|
| **FAM72A**                                                    |          |                    |         |
| a.                                                            |          |                    |         |
| Gender(Male vs. Female)                                       | 497      | 0.954(0.711–1.279) | 0.752   |
| Age(>70 vs. <=70)                                             | 487      | 1.464(1.081–1.982) | 0.014   |
| Number pack years smoked(>40 vs. <=40)                       | 341      | 1.026(0.714–1.475) | 0.888   |
| Race(Other vs. White)                                        | 497      | 1.265(0.797–2.008) | 0.061   |
| Tumor site(Upper lobe vs. Other)                              | 497      | 1.156(0.862–1.552) | 0.333   |
| EGFR status(Mut vs. Wt)                                       | 266      | 1.265(0.797–2.008) | 0.319   |
| ALK status(Mut vs. Wt)                                        | 236      | 1.713(0.938–3.128) | 0.080   |
| KRAS status(Mut vs. Wt)                                       | 302      | 1.257(0.778–2.032) | 0.351   |
| T stage(T2/T3/T4 vs. T1)                                     | 494      | 1.678(1.187–2.373) | 0.003   |
| M stage(M1 vs. M0)                                            | 355      | 2.129(1.243–3.648) | 0.006   |
| Pathologic stage(StageII/Stage III/Stage IV vs. Stage I)      | 490      | 2.629(1.924–3.591) | <0.001  |
| **FAM72A** (High vs. Low)                                    | 497      | 1.719(1.277–2.313) | <0.001  |
| b.                                                            |          |                    |         |
| Age(>70 vs. <=70)                                             |          | 1.564(1.139–2.148) | 0.006   |
| T stage(T2/T3/T4 vs. T1)                                     |          | 1.232(0.856–1.774) | 0.260   |
| N stage(N2/N3 vs. N0/N1)                                     |          | 1.169(0.782–1.746) | 0.447   |
| **FAM72A** (High vs. Low)                                    |          | 1.714(1.250–2.351) | 0.001   |
| **FAM72B**                                                    |          |                    |         |
| a.                                                            |          |                    |         |
| Gender(Male vs. Female)                                       | 497      | 0.954(0.711–1.279) | 0.752   |
| Age(>70 vs. <=70)                                             | 487      | 1.464(1.081–1.982) | 0.014   |
| Number pack years smoked(>40 vs. <=40)                       | 341      | 1.026(0.714–1.475) | 0.888   |
| Race(Other vs. White)                                        | 497      | 1.265(0.797–2.008) | 0.061   |
| Tumor site(Upper lobe vs. Other)                              | 497      | 1.156(0.862–1.552) | 0.333   |
| EGFR status(Mut vs. Wt)                                       | 266      | 1.265(0.797–2.008) | 0.319   |
| ALK status(Mut vs. Wt)                                        | 236      | 1.713(0.938–3.128) | 0.080   |
| KRAS status(Mut vs. Wt)                                       | 302      | 1.257(0.778–2.032) | 0.351   |
| T stage(T2/T3/T4 vs. T1)                                     | 494      | 1.678(1.187–2.373) | 0.003   |
| M stage(M1 vs. M0)                                            | 355      | 2.129(1.243–3.648) | 0.006   |
| Pathologic stage(StageII/Stage III/Stage IV vs. Stage I)      | 490      | 2.629(1.924–3.591) | <0.001  |
| **FAM72B** (High vs. Low)                                    | 497      | 1.719(1.277–2.313) | <0.001  |
| b.                                                            |          |                    |         |
| Age(>70 vs. <=70)                                             |          | 1.595(1.160–2.193) | 0.004   |
| T stage(T2/T3/T4 vs. T1)                                     |          | 1.257(0.875–1.807) | 0.216   |
| N stage(N2/N3 vs. N0/N1)                                     |          | 1.131(0.755–1.694) | 0.551   |
| Pathologic stage(StageII/Stage III/Stage IV vs. Stage I)      | 490      | 2.326(1.631–3.318) | 0.001   |
| **FAM72B** (High vs. Low)                                    |          | 1.776(1.289–2.446) | <0.001  |
| **FAM72C**                                                    |          |                    |         |
| a.                                                            |          |                    |         |
| Gender(Male vs. Female)                                       | 497      | 0.954(0.711–1.279) | 0.752   |
| Age(>70 vs. <=70)                                             | 487      | 1.464(1.081–1.982) | 0.014   |
| Number pack years smoked(>40 vs. <=40)                       | 341      | 1.026(0.714–1.475) | 0.888   |
| Race(Other vs. White)                                        | 497      | 1.265(0.797–2.008) | 0.061   |
| Tumor site(Upper lobe vs. Other)                              | 497      | 1.156(0.862–1.552) | 0.333   |
| EGFR status(Mut vs. Wt)                                       | 266      | 1.265(0.797–2.008) | 0.319   |
| ALK status(Mut vs. Wt)                                        | 236      | 1.713(0.938–3.128) | 0.080   |
| KRAS status(Mut vs. Wt)                                       | 302      | 1.257(0.778–2.032) | 0.351   |
replication, suggested that FAM72 is related to cell growth, division, and proliferation, further supporting its relationship with tumorigenesis. Other enriched terms were related to the centrosome, microtubule, and chromosome, and these findings need to be confirmed in further studies. A GSEA indicated roles in EGFR signaling, lung cancer poor survival, undifferentiated cancer, proliferation, and cell cycle pathways. Evan et al. reported that the excessive accumulation of cancer cells results from excessive cell proliferation and inadequate apoptosis. It is possible that FAM72 promotes tumorigenesis and contributes to a poor prognosis by similar mechanisms.

Immunotherapy is a promising approach in tumor therapy. The level of T cell immune infiltration is related to the efficacy of immunotherapy and is therefore the focus of current cancer immunotherapy research [15]. A large number of studies have shown that high levels of B cells and T cells, such as adenocarcinoma B cells and breast CD8 T, are associated with a better OS in many types of cancer, including LUAD [16]. NK cells are important mediators of anti-tumor immunity and ultimately participate in malignant cell killing [17]. Our results showed that FAM72A–D expression levels are positively correlated with PDCD1 (PD1) and CD274 (PD-L1) expression levels. High levels of PD-L1 have been detected in many tumors, including NSCLC, and are associated with poor prognosis [18]. However, some studies have
indicated that elevated PD-L1 may be related to a better response to immunotherapy. A randomized phase 3 trial of pembrolizumab and docetaxel in patients with PD-L1-positive tumors suggested that the survival benefit was associated with PD-L1 expression (50% expression of PD-L1, HR = 0.53; 1–49% expression, HR = 0.76) [19]. Another study has shown that patients with PD-L1 overexpression have better clinical outcomes after anti-PD-1 therapy than those of patients with low expression [20]. Our results indicated that FAM72 is a candidate predictive biomarker for the efficacy of immunotherapy and is associated with prognosis in patients with LUAD receiving immunotherapy.

Several studies have demonstrated an inverse relationship between hypomethylation and gene expression in NSCLC [21, 22]. Sato et al. indicated that high gene expression induced by hypomethylation is associated with poor prognosis in NSCLC [23, 24]. Previous studies have shown that high FAM72 expression is associated with hypomethylation and outcomes in cancer [11, 12]. We found that FAM72A–D show hypomethylation and that the hypomethylation level is associated with a poor outcome.

---

**Figure 3.** Nomogram for predicting the probability of 1-, 3- and 5-year OS for LUAD patients. (A–D) A nomogram that integrates FAM72A–D and other prognostic factors in LUAD from TCGA data.
Figure 4. Calibration curve for predicting the probability of 1-, 3- and 5-year OS for LUAD patients. (A–D) The calibration curve of the nomogram in LUAD from TCGA data.
Figure 5. Functional enrichment of FAM72A-D in LUAD. (A–D) Gene ontology (GO) enrichment analysis of FAM72A-D and its co-expression genes in Metascape. The GO enriched terms are colored by p-value, where terms containing more genes tend to have more significant p-value.
Figure 6. An interactive network of the top enrichment terms. (A-D) It is colored by cluster-ID. Distinct colors are various enrichment pathways of FAM72A-D correlated genes.
Figure 7. The top 20 pathways were differentially enriched according to the level of NES in FAM72A-D related LUAD. (A–D) The enrichment plot was obtained from the gene set enrichment analysis (GSEA).
Figure 8. The functional pathways and gene alteration of FAM72A-D in LUAD. (A) Several pathways were enriched in FAM72A-D related LUAD, including the proliferation, EGFR signaling, undifferentiated cancer, lung cancer poor survival and cell cycle; (B, C) Genetic alteration in FAM72A-D and its association with OS of LUAD patients.
Table 3. The association between the expression level of FAM72A-D and the immune infiltration in the tumor microenvironment.

| Immune cell                     | Spearman correlation | P-value |
|---------------------------------|----------------------|---------|
| **FAM72A**                      |                      |         |
| Plasmacytoid dendritic cell     | -0.275               | <0.001  |
| Natural killer cell             | -0.134               | 0.002   |
| Monocyte                        | -0.204               | <0.001  |
| Mast cell                       | -0.365               | <0.001  |
| Macrophage                      | -0.149               | 0.001   |
| Immature dendritic cell         | -0.184               | <0.001  |
| Eosinophil                      | -0.379               | <0.001  |
| Activated dendritic cell        | -0.161               | <0.001  |
| Type 2 T helper cell            | 0.239                | <0.001  |
| Type 17 T helper cell           | -0.221               | <0.001  |
| Type 1 T helper cell            | -0.135               | 0.002   |
| T follicular helper cell        | -0.219               | <0.001  |
| Memory B cell                   | 0.430                | <0.001  |
| Immature B cell                 | -0.134               | 0.003   |
| Gamma delta T cell              | 0.106                | 0.017   |
| Effector memory CD4 T cell      | 0.198                | <0.001  |
| Central memory CD4 T cell       | -0.180               | <0.001  |
| Activated CD4 T cell            | 0.517                | <0.001  |
| Activated B cell                | -0.222               | <0.001  |
| **FAM72B**                      |                      |         |
| Plasmacytoid dendritic cell     | -0.225               | <0.001  |
| Natural killer T cell           | -0.132               | 0.003   |
| Monocyte                        | -0.185               | <0.001  |
| Mast cell                       | -0.347               | <0.001  |
| Macrophage                      | -0.114               | 0.010   |
| Immature dendritic cell         | -0.148               | 0.001   |
| Eosinophil                      | -0.372               | <0.001  |
| Activated dendritic cell        | -0.118               | 0.008   |
| Type 2 T helper cell            | 0.297                | <0.001  |
| Type 17 T helper cell           | -0.197               | <0.001  |
| T follicular helper cell        | -0.190               | <0.001  |
| Memory B cell                   | 0.484                | <0.001  |
| Immature B cell                 | -0.099               | 0.025   |
| Gamma delta T cell              | 0.163                | <0.001  |
| Effector memory CD4 T cell      | 0.237                | <0.001  |
| Central memory CD4 T cell       | -0.162               | <0.001  |
| Activated CD4 T cell            | 0.563                | <0.001  |
| Activated B cell                | -0.188               | <0.001  |
| **FAM72C**                      |                      |         |
| Plasmacytoid dendritic cell     | -0.295               | <0.001  |
| Natural killer cell             | -0.145               | 0.001   |
| Monocyte                        | -0.178               | <0.001  |
| Mast cell                       | -0.402               | <0.001  |
| Macrophage                      | -0.132               | 0.003   |
| Immature dendritic cell         | -0.209               | <0.001  |
| Eosinophil                      | -0.375               | <0.001  |
|                                | Spearman correlation | P-value |
|--------------------------------|----------------------|---------|
| **PDCD1**                      |                      |         |
| FAM72A                         | 0.191                | <0.001  |
| FAM72B                         | 0.211                | <0.001  |
| FAM72C                         | 0.150                | 0.001   |
| FAM72D                         | 0.163                | <0.001  |
| **CD274**                      |                      |         |
| FAM72A                         | 0.226                | <0.001  |
| FAM72B                         | 0.248                | <0.001  |
| FAM72C                         | 0.104                | 0.012   |
| FAM72D                         | 0.147                | 0.001   |

Table 4. Correlation between the expression of PDCD1/CD274 and the expression of FAM72A-D.
prognosis in LUAD. Therefore, FAM72 expression may be epigenetically regulated by DNA hypomethylation, providing an additional prognostic factor.

Although our findings improve our understanding of the relationship between FAM72A–D and LUAD, our study had some limitations. First, the data were obtained from public databases, and data quality cannot be assessed. Further experimental studies are needed to confirm our results. Second, the specific role of FAM72 in the development of LUAD should be comprehensively evaluated, and a broader range of clinical factors should be considered. These analyses were limited by a lack of some information in public databases. Third, the correlation between FAM72 expression at the mRNA and protein levels needs to be verified by cellular and clinical experiments. Fourth, we cannot determine the direct mechanisms by which FAM72 promotes the development of LUAD, which should be a focus of future research. To further investigate the mechanism underlying the effects of FAM72 in LUAD, we plan to conduct cellular experiments in the near future.

Figure 9. The methylation of FAM72A/B/D in LUAD. (A–C) The visualization between the methylation level and the FAM72A/B/D expression; (D) The Kaplan-Meier survival of the promoter methylation of FAM72B.
In summary, the results of the present study partially revealed the roles of FAM72A-D in LUAD, providing a potential therapeutic and prognostic biomarker. In particular, we found that FAM72 may be a molecular marker of poor prognosis in LUAD. FAM72 mutations were associated with poor survival. Additionally, FAM72 may be a predictive biomarker for the efficacy of immunotherapy as well as prognosis in patients with LUAD undergoing immunotherapy. Finally, hypomethylation was associated with high FAM72 expression, providing additional insight into the molecular mechanisms underlying LUAD.

**MATERIALS AND METHODS**

**Clinical information from TCGA and GEO databases**

Gene expression data (HTSeq-Counts and HTSeq-FPKM), phenotype data, and detailed clinicopathological information for TCGA-LUAD were obtained using the UCSC Xena browser (version: 07-20-2019, https://xenabrowser.net/datapages/). Sequence data were retrieved using the Illumina HiSeq RNA_Seq platform. HTSeq-FPKM gene expression data were transformed into TPM (transcripts per million reads) for subsequent analyses. TPM yields more similar results to those produced by a microarray approach and facilitates comparisons among samples [25]. The inclusion criteria for data retrieval from the two databases were as follows: (1) pathological diagnosis of adenocarcinoma, (2) complete gene expression data, and (3) complete survival information. GEO datasets used GPL570, GPL6480 and GPL6884 platforms. The probe ID was converted to the gene symbol according to the related annotation file, and the average expression values for multiple probes corresponding to the same gene were calculated. Data used in the study were in accordance with publication guidelines provided by TCGA and GEO. No studies directly involving human participants or animal experiments were included. Ethics approval and informed consent were not required.

**Statistical analysis**

All statistical analysis was performed using the IBM SPSS statistical package (SPSS 26.0) and R (4.0.2). The Wilcoxon rank-sum test was used to compare the expression of FAM72A–D between LUAD and normal groups. The relationships between clinicopathologic parameters and FAM72A–D expression levels were evaluated with Wilcoxon signed-rank tests. Clinicopathologic parameters (age, gender, pack-years, race, tumor site, EGFR status, ALK status, KRAS status, T stage, N stage, M stage, pathological stage, and gene expression) associated with OS were evaluated by Cox regression analyses. Univariate and multivariate analyses were performed by applying the Cox logistic regression model to identify independent predictors, including age at diagnosis (ref. ≤70 years), gender (ref. male), pack-years (ref. <40), race (ref. other race), tumor site (ref. other site), EGFR status (ref. wt), ALK status (ref. wt), KRAS status (ref. wt), T stage (ref. T1), N stage (ref. NO), M stage (ref. M0), pathological stage (ref. I), and FAM72A–D expression (ref. Low). The 95% confidence interval (CI) of the HR was measured to evaluate the hazard risk for individual factors. All tests were two-sided, and P-values of less than 0.05 were considered statistically significant.

**Over-expression of FAM72A-D in patients with LUAD**

FAM72 expression levels in patients with LUAD were compared between tumor tissues and normal tissues. In addition, the corrplot R package (version:0.84, https://cran.r-project.org/web/packages/corrplot/index.html) was used to explore correlations between FAM72A, B, C, and D levels in LUAD. The AUC values for FAM72A–D were evaluated using pROC R package (version:1.16.2, https://cran.r-project.org/web/packages/pROC/index.html) and ggplot2 R package (version:3.3.2, https://cran.r-project.org/web/packages/ggplot2/index.html).

**Association between FAM72 and survival**

A survival curve was generated using the survival R package (v. 0.1.3, https://cran.r-project.org/web/packages/survivalAnalysis/index.html) and survminer R package (v. 0.4.8, https://cran.r-project.org/web/packages/survminer/index.html). Furthermore, the prognostic value of the risk model was evaluated using four independent datasets from GEO (https://www.ncbi.nlm.nih.gov/geo/), GSE13213 (n = 117), GSE30219 (n = 85), GSE412710 (n = 181), and GSE50081 (n = 127).

**Construction and evaluation of the nomogram and prognostic model**

A nomogram was constructed based on the optimal multivariate Cox regression analysis to predict the 1-year, 3-year, and 5-year survival probabilities. The rms R package (v. 6.0-1, https://cran.r-project.org/web/packages/rms/index.html) was used to produce a nomogram. The concordance index (C-index) and calibration plot are frequently used to evaluate the quality of nomogram models. The C-index and calibration plot were evaluated using the Hmisc R package (v. 4.4-1, https://cran.r-project.org/web/packages/Hmisc/index.html). In this study, the C-index was used to determine the discrimination ability with 1000 bootstrap replicated. As the C-index increases, the prediction accuracy increases.
The calibration curve was visually evaluated by mapping the nomogram predictions to observed probabilities, and a 45° line represented optimal predictive values.

**Functional enrichment analysis**

GEPIA, a database based on the UCSC Xena project (http://xena.ucsc.edu), enables dynamic analyses and visualization of TCGA gene expression profile data [26]. In our study, GEPIA2.0 (http://geopia2.cancer-pku.cn/) was used to find genes with highly correlated expression levels to those of FAM72A–D in LUAD. The correlations between levels of these genes and FAM72A–D were greater than 0.62. Then, the functions of FAM72A–D and genes with correlated expression in TCGA-LUAD were predicted by a GO enrichment analysis, as implemented using Metascape (http://metascape.org) [27].

**Gene set enrichment analysis**

Expression profiles (HTSeq-Counts) were compared between high and low FAM72A–D expression groups to identify differentially expressed genes using the DESeq2 R package (v. 1.28.1, http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html) in R (4.0.2). A GSEA of approximately 20,000 differentially expressed genes was performed. GSEA determines whether a set of prior defined genes show statistically significant and consistent differences between two biological states [28, 29]. In this study, GSEA was performed using the Molecular Signatures Database (MSigDB) Collection (c2.all.v7.0.entrez.gmt) of the clusterProfiler R package (3.18.0, http://bioconductor.org/packages/release/bioc/html/clusterProfiler.html) to identify statistically significant pathway differences between high and low FAM72A–D expression groups in LUAD. The expression level of FAM72A–D was used as a phenotype label. Pathway terms with adjusted P-value < 0.05 and FDR q-value < 0.25 were considered significantly enriched.

**FAM72A–D mutations and prognosis**

cBioPortal (https://www.cbioportal.org) can be used to explore, visualize, and analyze multidimensional cancer genome data [30]. In our study, we analyzed the genomic profiles of FAM72A–D with a z-score threshold of ±1.8. Genetic mutations in FAM72A–D and their association with OS were evaluated.

**Analysis of immune infiltration with respect to FAM72A–D expression by ssGSEA**

To evaluate correlations between FAM72A–D and levels of immune cell infiltration, the ssGSEA (single-sample Gene Set Enrichment Analysis) method was applied using the GSVA package (v. 1.36.3, http://www.bioconductor.org/packages/release/bioc/html/GSVA.html). The immune reference set was obtained from the literature (http://dx.doi.org/10.1016/j.celrep.2016.12.019) [31]. The relative levels of 28 types of tumor-infiltrating immune cells in the immunocyte signatures, including 782 genes for prediction in individual tissue samples, were evaluated. Based on 28 immunocyte signature genes in the literature, a relative enrichment score for every immunocyte was quantified from the gene expression profile of each tumor sample [32]. The following 28 types of immune cells were included: activated CD4 T cells, activated CD8 T cells, activated B cells, central memory CD4 T cells, central memory CD8 T cells, effector memory CD4 T cells, effector memory CD8 T cells, gamma delta T cells, regulatory T cells, type-1 T helper cells, type-2 T helper cells, type-17 T helper cells, follicular helper T cells, CD56 dim natural killer cells, CD56 bright natural killer cells, natural killer cells, natural killer T cells, immature B cells, memory B cells, activated dendritic cells, immature dendritic cells, plasmacytoid dendritic cells, mast cells, myeloid-derived suppressor cells, monocytes, eosinophils, neutrophils, and macrophages. The relationships between FAM72A–D and levels of immune cell infiltration were evaluated by Spearman correlation coefficients.

**Correlation between FAM72A–D expression and methylation**

Studies have shown that FAM72 is related to methylation. Therefore, we further analyzed the relationship between FAM72A–D and methylation. Spearman correlation coefficients were determined to evaluate the correlation between FAM72A–D and methylation levels in TCGA-LUAD. For this analysis, MethSurv (https://biit.cs.ut.ee/methsurv/) was used, which is a web tool for univariate and multivariate survival analyses based on DNA methylation biomarkers using TCGA data, containing 25 different types of cancer and 7,358 patients [33].

**Abbreviations**

FAM72A-D: Family with sequence similarity 72 member A-D; TCGA: The Cancer Genome Atlas; GEO: Gene Expression Omnibus; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; GO: gene ontology; GSEA: gene set enrichment analysis; OS: overall survival; NSCLC: non-small cell lung cancer; DEGs: differentially expressed genes; ES: enrichment score; NES: normalized ES; FDR: false discovery rate.

**AUTHOR CONTRIBUTIONS**

YL Yu, ZP Wang and JC Li designed this study. YL Yu and QH Zheng contributed to the data collection.
YL Yu and ZP Wang analyzed the data. JC Li supervised the study. YL. Yu and ZP Wang wrote the manuscript. All authors read and revised the manuscript.

ACKNOWLEDGMENTS

We sincerely thank the public databases, including TCGA, GEO, GEPIA, Metascape, cBioPortal and MethSurv, for providing open access. Moreover, we thank editage (http://www.fabiao@editage.cn) for editing this manuscript.

CONFLICTS OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.

FUNDING

Innovation of Science and Technology, Fujian Province (Grant number:2018Y9111); and the Financial Foundation of Fujian Province (Grant number: (2020)729).

REFERENCES

1. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015; 1:15009. https://doi.org/10.1038/nrdp.2015.9 PMID:27188576

2. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511:543–50. https://doi.org/10.1038/nature13385 PMID:25079552

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68:7–30. https://doi.org/10.3322/caac.21442 PMID:29313949

4. Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, Auburger J, Nevinny-Stickel M, Sterlacci W, Tzankov A, Jamnig H, Kohler K, Zabernigg A, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung Cancer. 2015; 87:193–200. https://doi.org/10.1016/j.lungcan.2014.12.006 PMID:25564398

5. Chen D, Wang R, Yu C, Cao F, Zhang X, Yan F, Chen L, Zhu H, Yu Z, Feng J. FOX-A1 contributes to acquisition of chemoresistance in human lung adenocarcinoma via transactivation of SOX5. EBioMedicine. 2019; 44:150–61. https://doi.org/10.1016/j.ebiom.2019.05.046 PMID:31147293

6. Heese K. The protein p17 signaling pathways in cancer. Tumour Biol. 2013; 34:4081–87. https://doi.org/10.1007/s13277-013-0999-1 PMID:23900679

7. Kutzner A, Pramanik S, Kim PS, Heese K. All-or-(N)One - an epistemological characterization of the human tumorigenic neuronal paralogous FAM72 gene loci. Genomics. 2015; 106:278–85. https://doi.org/10.1016/j.ygeno.2015.07.003 PMID:26206076

8. Nehar S, Mishra M, Heese K. Identification and characterisation of the novel amyloid-beta peptide-induced protein p17. FEBS Lett. 2009; 583:3247–53. https://doi.org/10.1016/j.febslet.2009.09.018 PMID:19755123

9. Guo C, Zhang X, Fink SP, Platzer P, Wilson K, Willson JK, Wang Z, Markowitz SD. Ugene, a newly identified protein that is commonly overexpressed in cancer and binds uracil DNA glycosylase. Cancer Res. 2008; 68:6118–26. https://doi.org/10.1158/0008-5472.CAN-08-1259 PMID:18676834

10. Rajan P, Stockley J, Sudbery IM, Fleming JT, Hedley A, Kalna G, Sims D, Ponting CP, Heger A, Robson CN, McMenemin JI, Tzankov A, Tzankov A, Chen JF. Hydroxymethylome of multiple myeloma identifies a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer. 2014; 14:977. https://doi.org/10.1186/1471-2407-14-977 PMID:25919703

11. Rahane CS, Kutzner A, Heese K. A cancer tissue-specific FAM72 expression profile defines a novel glioblastoma multiform (GBM) gene-mutation signature. J Neurooncol. 2019; 141:57–70. https://doi.org/10.1007/s11060-018-03029-3 PMID:30414097

12. Chatonnet F, Pignarre A, Sérandour AA, Caron G, Avner S, Robert N, Kassambara A, Laurent A, Bizot M, Agirre X, Prosper F, Martin-Subero JI, Moreaux J, et al. The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation. Haematologica. 2020; 105:774–83. https://doi.org/10.3324/haematol.2019.222133 PMID:31221779

13. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017; 8:1–20. https://doi.org/10.5306/wico.v8i1.1 PMID:28246582

14. Rahane CS, Kutzner A, Heese K. Establishing a human adrenocortical carcinoma (ACC)-specific gene mutation signature. Cancer Genet. 2019; 230:1–12.
15. Borst J, Ahrends T, Babala N, Melief CJ, Kastenmüller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018; 18:635–47. https://doi.org/10.1038/s41577-018-0044-0 PMID:30057419

16. Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG. Genomic analysis of immune cell infiltrates across 11 tumor types. J Natl Cancer Inst. 2016; 108: djw144. https://doi.org/10.1093/jnci/djw144 PMID:27335052

17. Prince VE, Pickett FB. Splitting pairs: the diverging fates of duplicated genes. Nat Rev Genet. 2002; 3:827–37. https://doi.org/10.1038/nrg928 PMID:12415313

18. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015; 21:24–33. https://doi.org/10.1016/j.molmed.2014.10.009 PMID:25440090

19. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387:1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7 PMID:26712084

20. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015; 14:847–56. https://doi.org/10.1158/1535-7163.MCT-14-0983 PMID:25695955

21. Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, et al. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 2014; 15:1079. https://doi.org/10.1186/1471-2164-15-1079 PMID:25486910

22. Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, Lizio M, Itoh M, Kawai H, Lassmann T, Carminci P, Hayashizaki Y, Forrest AR, et al. Integrative CAGE and DNA methylation profiling identify epigenetically regulated genes in NSCLC. Mol Cancer Res. 2017; 15:1354–65. https://doi.org/10.1158/1541-7786.MCR-17-0191 PMID:28698358

23. Sato T, Soejima K, Arai E, Hamamoto J, Yasuda H, Arai D, Ishioka K, Ohgino K, Naoki K, Kohno T, Tsuta K, Watanabe S, Kanai Y, Betsuyaku T. Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer. Oncol Rep. 2015; 34:1137–45. https://doi.org/10.3892/or.2015.4082 PMID:26134684

24. Noguera-Uclés JF, Boyero L, Salinas A, Cordero Varela JA, Benedetti JC, Bernabé-Caro R, Sánchez-Gastaldo A, Alonso M, Paz-Ares L, Molina-Pinelo S. The roles of imprinted SLC22A18 and SLC22A18AS5 gene overexpression caused by promoter CpG island hypomethylation as diagnostic and prognostic biomarkers for non-small cell lung cancer patients. Cancers (Basel); 2020; 12:2075. https://doi.org/10.3390/cancers12082075 PMID:32726996

25. Zhao S, Ye Z, Stanton R. Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols. RNA. 2020; 26:903–9. https://doi.org/10.1261/rna.074922.120 PMID:32284352

26. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45:W98–102. https://doi.org/10.1093/nar/gkx247 PMID:28407145

27. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10:1523. https://doi.org/10.1038/s41467-019-09234-6 PMID:30944313

28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102:15545–50. https://doi.org/10.1073/pnas.0506580102 PMID:16199517

29. Mootha VK, Lindgren CM, Eriksson FF, Subramanian A, Sihag S, Lehár J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houlist N, Daly MJ, Patterson N, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34:267–73. https://doi.org/10.1038/ng1180 PMID:12808457

30. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:p1l.
31. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017; 18:248–62. https://doi.org/10.1016/j.celrep.2016.12.019 PMID:28052254

32. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39:782–95. https://doi.org/10.1016/j.immuni.2013.10.003 PMID:24138885

33. Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018; 10:277–88. https://doi.org/10.2217/epi-2017-0118 PMID:29264942